Log in

OTCMKTS:NRXGQ - NephroGenex Stock Price, Forecast & News

Add
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume2,000 shs
Average Volume26,223 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
NephroGenex, Inc is a pharmaceutical company. The Company is focused on the development of therapeutics to treat kidney disease. The Company has paused the clinical program of its product candidate, oral Pyridorin, for the treatment of diabetic nephropathy. The Company was primarily focused on the Phase III Pyridorin program, and other planned clinical and nonclinical studies and other work needed to submit Pyridorin for acute kidney injury (AKI), as well as the treatment of diabetic nephropathy in patients with Type II diabetes for regulatory approval in the United States and Europe. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolOTCMKTS:NRXGQ
Previous SymbolNASDAQ:NRX
CUSIPN/A
Phone+1-609-5538887

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive NRXGQ News and Ratings via Email

Sign-up to receive the latest news and ratings for NRXGQ and its competitors with MarketBeat's FREE daily newsletter.


NephroGenex (OTCMKTS:NRXGQ) Frequently Asked Questions

What is NephroGenex's stock symbol?

NephroGenex trades on the OTCMKTS under the ticker symbol "NRXGQ."

Has NephroGenex been receiving favorable news coverage?

Media headlines about NRXGQ stock have trended somewhat negative this week, according to InfoTrie Sentiment. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. NephroGenex earned a daily sentiment score of -1.4 on InfoTrie's scale. They also gave news articles about the healthcare company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the immediate future. View News Stories for NephroGenex.

What other stocks do shareholders of NephroGenex own?

Who are NephroGenex's key executives?

NephroGenex's management team includes the folowing people:
  • John P. Hamill CPA, Chief Executive Officer, Chief Financial Officer

How do I buy shares of NephroGenex?

Shares of NRXGQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is NephroGenex's official website?

The official website for NephroGenex is http://www.nephrogenex.com/.

How can I contact NephroGenex?

NephroGenex's mailing address is PO Box 400, JAMISON, PA 18929-0400, United States. The healthcare company can be reached via phone at +1-609-5538887.


MarketBeat Community Rating for NephroGenex (OTCMKTS NRXGQ)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  95 (Vote Outperform)
Underperform Votes:  75 (Vote Underperform)
Total Votes:  170
MarketBeat's community ratings are surveys of what our community members think about NephroGenex and other stocks. Vote "Outperform" if you believe NRXGQ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NRXGQ will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/14/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel